Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases

US11723861B2 · kind B2 · utility

Assignee

• NOVALIQ GMBH · DE

Inventors

• Bernhard Günther · Dossenheim, DE
• Frank LÖSCHER · Schriesheim, DE
• Kirsten EICKHOFF · Aschaffenburg, DE

Key dates

• Filing date: Sep 25, 2018
• Grant date: Aug 15, 2023
• Expiry date: May 10, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.